3.259USD-47.35%Mkt Cap: 12.27M USDP/E: —Last update: 2026-06-01
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fu…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap12.27M USD
Enterprise Value-3.22M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-55.84M USD
Revenue/Share—
Last Price3.259 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS65343E1082
Valuation
P/E (Trailing)—
P/E (Forward)-0.74
PEG—
EV/EBITDA0.06
EV/Revenue—
P/S—
P/B0.62
EPS (TTM)-16.82
EPS (Forward)-8.35
52W Range
2.8453% of range15.74
52W High15.74 USD
52W Low2.845 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.81%
ROA-111.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.61M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-221.14%
Net Debt-25.86M USD
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity0.15
Current Ratio4.61
Quick Ratio4.32
Book Value/Sh9.968 USD
Cash/Share8.234 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 14, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)19.33 USD
Target Range15.00 USD – 25.00 USD
# Analysts3
Ownership
Shares Out.3.61M
Float2.28M
Insiders14.84%
Institutions62.54%
Short Interest
Short Ratio1.0d
Short % Float1.61%
Short % Out.1.61%
Shares Short58.02K
Short (prev mo.)72.01K
Technical
SMA 5010.14 (-67.9%)
SMA 2009.992 (-67.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)75.18K
Avg Vol (10d)49.78K
Technical Indicators
RSI (14)30.8
MACD-1.0300
MACD Signal-0.6767
MACD Hist.-0.3534
BB Upper11.89 USD
BB Middle8.952 USD
BB Lower6.016 USD
BB Width65.60%
ATR (14)1.121 USD
Vol Ratio (20d)0.20x